Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Phase 3 crawled date : 2021 - 12 - 14 save search
Data from two Phase 3 studies demonstrating fitusiran significantly reduced bleeds in people with hemophilia A or B, with or without inhibitors, were featured at ASH’s plenary and late-breaking sessions
Published: 2021-12-14 (Crawled : 15:30) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -3.62%
H: 0.0%
C: -0.56%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -0.51%
H: 0.0%
C: 0.0%
phase 3
Galera Announces Primary Endpoint Met Statistical Significance in Corrected Topline Efficacy Data of Phase 3 ROMAN Trial of Avasopasem
Published: 2021-12-14 (Crawled : 15:30) - biospace.com/
GRTX | $0.1833 -1.45% -1.47% 800K
|
Health Technology
|
| O: 105.07%
H: 22.26%
C: -4.59%
trial topline phase 3 avasopasem roman trial
Cidara Therapeutics and Mundipharma Announce Positive Topline Results from the Global Phase 3 Pivotal ReSTORE Trial of Rezafungin for the Treatment of Candidemia and Invasive Candidiasis
Published: 2021-12-14 (Crawled : 15:30) - biospace.com/
CDTX | $0.6855 -5.06% -5.32% 350K
|
Health Technology
|
| O: -15.03%
H: 0.36%
C: -14.8%
treatment trial therapeutics topline results positive results topline phase 3 candidemia
Emmaus Life Sciences Presents Positive Transfusion Data from a Post-Hoc Analysis of its Phase 3 Clinical Study of Endari® in Patients With Sickle Cell Disease at the 63rd American Society of Hematology (ASH) Annual Meeting
Published: 2021-12-14 (Crawled : 14:30) - biospace.com/
EMMA | $0.1138 385.44% 300
|
Professional, Scientific, and T...
|
| O: -0.33%
H: 2.65%
C: -2.65%
endari ema transfusion disease cel positive life science phase 3
INOVIO Highlights Key Updates on Phase 3 Program for VGX-3100, its DNA-based Immunotherapy for the Treatment of Cervical HSIL Caused by HPV-16 and/or HPV-18
Published: 2021-12-14 (Crawled : 13:30) - inovio.com
INO 4 d | $9.68 -5.1% -5.37% 350K
|
Health Technology
|
| O: -1.56%
H: 0.67%
C: -1.34%
vgx-3100 treatment hpv immunotherapy therapy phase 3
Centessa Pharmaceuticals Initiates Global Phase 3 ACTION Study of Lixivaptan in Autosomal Dominant Polycystic Kidney Disease
Published: 2021-12-14 (Crawled : 13:30) - biospace.com/
CNTA | $10.555 0.24% 0.24% 150K
|
Manufacturing
|
| O: -6.56%
H: 7.45%
C: -6.09%
als disease phase 3 kidney
TG Therapeutics Announces Data from the UNITY-CLL Phase 3 Trial Presented at the 63rd American Society of Hematology (ASH) Annual Meeting
Published: 2021-12-14 (Crawled : 12:30) - globenewswire.com
TGTX | $13.79 -1.43% -1.45% 3.7M
|
Health Technology
|
| O: -5.49%
H: 2.43%
C: -2.68%
ema trial therapeutics phase 3
Atara Biotherapeutics Announces Positive Results from Pivotal Phase 3 Trial (ALLELE) of Tab-cel® at the 63rd American Society of Hematology (ASH) Annual Meeting
Published: 2021-12-14 (Crawled : 06:00) - biospace.com/
ATRA | $0.6755 -2.34% -2.4% 1.6M
|
Health Technology
|
| O: -4.53%
H: 4.22%
C: 2.01%
cel ema trial therapeutics positive results tab-cel positive results phase 3 iot
New Results from Phase 1 Study of Cemdisiran + Pozelimab Presented at ASH Annual Meeting 2021
Published: 2021-12-14 (Crawled : 03:00) - alnylam.com
ALNY | $144.315 -0.58% -0.59% 700K
|
Health Technology
|
| O: 6.02%
H: 2.03%
C: -0.29%
phase 1 results phase 2 phase 3
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.